Efficient and scalable synthesis of ketones via nucleophilic Grignard addition to nitriles using continuous flow chemistry
作者:Carlos Mateos、Juan A. Rincón、José Villanueva
DOI:10.1016/j.tetlet.2013.02.069
日期:2013.5
In the present Letter we report the development of efficient continuous flow chemistry conditions for the scalable preparation of ketones. This transformation is achieved via nucleophilic addition of Grignard reagents to the corresponding nitriles and imine hydrolysis by means of in-series plug flow reactors.
Direct Regioselective Reductive Allylation of Imines: Application to Synthesis of Oxazines with Halogenated Reagent
作者:Tao Ju、Ai-Ling Lu、Yu-Chao Zhou、Min Ge、Jing Sun、Ying Han、Chao-Guo Yan
DOI:10.1021/acs.orglett.3c03407
日期:2023.12.15
Oxazines are an important class of compounds in oxazine ligands and medical chemistry. Here, we describe a linear-selective allylation of imines with allyl electrophiles via cross-electrophile coupling reactions, followed by cyclization with halogenated reagents, providing a new strategy to afford oxazine compounds with a tetrasubstituted carbon center. Mechanistic studies indicate that α-amino carbanion
Factors Affecting the Rate of Hydrolysis of Ketimines
作者:J. B. Culbertson
DOI:10.1021/ja01154a102
日期:1951.10
US7498339B2
申请人:——
公开号:US7498339B2
公开(公告)日:2009-03-03
[EN] SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE SPIROPIPÉRIDINE GLYCINAMIDE
申请人:HOFFMANN LA ROCHE
公开号:WO2008084005A1
公开(公告)日:2008-07-17
[EN] The present invention is concerned with novel spiropiperidine glycinamide derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention and/or treatment of anxiety and depressive disorders and other diseases. In particular, the present invention is concerned with compounds of the general formula (I) wherein X, Y and R1 to R10 are as described herein. [FR] La présente invention concerne des dérivés innovants de spiropipéridine glycinamide en tant qu'antagonistes du récepteur V1a, leur fabrication, les compositions pharmaceutiques qui les contiennent et leur utilisation en tant que médicaments. Les composés actifs de la présente invention sont utilisables pour la prévention et/ou le traitement de l'anxiété et des troubles dépressifs et d'autres maladies. La présente invention concerne en particulier des composés de formule générale (I) dans laquelle X, Y et R1 à R10 sont tels que décrits ici.